AGA guideline update: Inpatient IBD management

What are the key updates in IBD inpatient care? 

The 2026 American Gastroenterological Association (AGA) Clinical Practice Update provides new best practice advice for evaluating and managing hospitalized adults with inflammatory bowel disease (IBD).¹ These statements address 13 critical aspects of inpatient care, with emphasis on early identification of complications, appropriate use of corticosteroids and rescue therapy, and coordinated surgical and discharge planning.

How has the recommended IBD inpatient evaluation changed?

Clear criteria for when hospitalization should be considered

Hospitalization is advised for patients with severe, treatment‑refractory disease or suspected complications, such as:

• Intestinal obstruction
• Intra‑abdominal abscess
• Perforation
• Severe malnutrition
• Failure to thrive
• Dehydration
• Electrolyte derangements

Urgent evaluation allows timely multidisciplinary management and rapid escalation of care.

Supportive care as the essential first step

Initial care requires an IBD‑focused history and physical examination, along with laboratory testing, including C-reactive protein (CRP) and fecal calprotectin (if available). All patients should also receive:

• Intravenous hydration
• Electrolyte repletion
• Treatment for anemia
• Screening for vitamin deficiencies, including vitamin B12 and vitamin D

Pain management should focus on treating underlying causes, with opioids generally avoided.

Early evaluation for IBD-related complications and infections

Patients hospitalized with diarrhea should undergo stool pathogen testing for Clostridioides difficile using a two‑step assay. Cytomegalovirus (CMV) infection should be assessed in those with worsening gastrointestinal symptoms, systemic toxicity, or steroid‑refractory symptoms. Cross‑sectional imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), is recommended for suspected obstruction, abscess, or toxic megacolon.

Objective assessment with biomarkers and early endoscopy

Inflammatory biomarkers – including CRP, leukocyte and platelet counts, and albumin – help assess disease activity, with CRP being especially useful for identifying acute severe ulcerative colitis (ASUC). Early endoscopic examination is recommended to evaluate disease activity, obtain mucosal biopsies, and rule out CMV. Endoscopy or flexible sigmoidoscopy within 48 hours is associated with reduced length of hospital stay.

What are the main IBD treatment updates?

Once disease severity and complications are defined, IBD management focuses on preventing complications and optimizing medical therapy.

Prophylactic anticoagulation for all hospitalized patients with IBD

Because IBD doubles the risk of venous thromboembolism, prophylactic anticoagulation with subcutaneous low‑molecular‑weight heparin or fondaparinux is recommended unless contraindicated. Decisions about extending prophylaxis post‑discharge should be individualized.

Severe ulcerative colitis: Corticosteroid dosing and early surgical involvement

People hospitalized with severe ulcerative colitis (UC) should receive intravenous methylprednisolone 60 mg (or equivalent). Dosing above this provides no additional benefit. Early surgical consultation is recommended given that approximately 10% of hospitalized patients with UC require surgery. Toxic megacolon is a highly morbid complication of IBD that warrants urgent evaluation and possible intervention.

Monitoring steroid response and determining non‑response

People with UC should be assessed for steroid response within 72 hours of treatment initiation using stool frequency and CRP (Oxford criteria). Lack of improvement by day 3 predicts high colectomy risk. Continuing IV steroids beyond 7 days without response offers no benefit.

Preparation for rescue therapy for steroid non-responders

Patients who do not respond to initial therapy should be considered for rescue therapy with infliximab, cyclosporine, or Janus kinase (JAK) inhibitors. Accelerated infliximab dosing may be considered in selected patients with high inflammatory burden or protein‑losing colopathy. JAK inhibitors may be used with standard or intensified dosing.

What are the updates in managing complications of Crohn’s disease?

Crohn’s disease with intestinal obstruction

Initial management emphasizes supportive measures:

• Bowel rest
• Nasogastric decompression
• IV fluid resuscitation

Subsequent evaluation with imaging determines the underlying cause of the obstruction – whether inflammatory, fibrotic, or adhesive – and informs further treatment. IV corticosteroids may be used when active inflammation is present, while surgery is indicated for fibrotic strictures or complications. Endoscopic dilation may be considered for short, non‑inflammatory strictures and after resolution of the acute obstruction.

Crohn’s disease with intra‑abdominal abscess

Management requires antibiotics and abscess drainage (for abscesses >2–3 cm) when feasible. Large or undrainable abscesses may be managed with IV antibiotics followed by surgery if needed. Once infection control is achieved, initiation of steroid‑sparing biologic therapy is appropriate to address underlying transmural inflammation.

Crohn’s disease with perianal involvement

Patients with active perianal disease require combined surgical and medical care. Examination under anesthesia and drainage of abscesses with seton placement are key steps. Anti‑tumor necrosis factor (TNF) therapy with antibiotics is the preferred medical approach. In patients with severe or refractory disease, colostomy or ileostomy diversion may be required to control sepsis or facilitate healing.

What are the expectations for patients with IBD prior to discharge?

Before discharge, patients with IBD should demonstrate stability or clear improvement in the condition that prompted hospitalization. Discharge does not require full normalization of biomarkers but should include:

• A documented outpatient plan (including steroid tapering and infusion scheduling)
• Coordination with outpatient clinicians
• Clear guidance for when to seek urgent care
• Early identification of barriers such as medication access, transportation, and prior authorizations

These measures aim to reduce recurrent readmissions and improve care continuity.

READ IBD GUIDELINES